Pharmacological Targets

A knowledge base of drug targets, used for the treatment of tuberculosis, and those considered as promising in the development of new pharmaceuticals. All pharmacological targets are differentiated into three categories: the targets of approved drugs (Launched); drugs targets studied in clinical trials (Clinical); targets of pharmacological substances investigated in preclinical studies (Preclinical). Relevant information indirectly characterizing the degree of reliability of the association of a particular target with the disease in question was included in our database.

One may browse the records in the database or search for a particular drug target using target name as a query.

Pharmacological targets are associated with links on the appropriate information in UniProt, KEGG and PDB.

Show entries

Search:

Target's name	UniProt	PDB	Kegg	Pharmacotheraputic application
Target's name	UniProt	PDB	Kegg	Launched	Clinical	Preclinical
Target's name	UniProt	PDB	Kegg	Pharmacotheraputic application
Target's name	UniProt	PDB	Kegg	Launched	Clinical	Preclinical
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial	Q07973				Cancer
1,4-Dihydroxy-2-naphthoyl-CoA synthase	P9WNP5					Tuberculosis
1-Acyl-sn-glycerol-3-phosphate acyltransferase beta precursor (isoform a)	O15120					Cancer
1-Acylglycerol-3-phosphate O-acyltransferase ABHD5	Q8WTS1					Cancer Diabetes
1-Deoxy-D-xylulose 5-phosphate reductoisomerase (Escherichia coli)	P45568					Malaria
1-Deoxy-D-xylulose 5-phosphate reductoisomerase (Mycobacterium smegmatis)	A0QVH7					Malaria
1-Deoxy-D-xylulose 5-phosphate reductoisomerase (Mycobacterium tuberculosis)	P9WNS1			Malaria,Tuberculosis
1-Deoxy-D-xylulose 5-phosphate reductoisomerase (Plasmodium falciparum)	Q8IKG4			Malaria		Tuberculosis
1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (isoform 1)	P19174					Cancer
1-Phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (isoform 2)	P19174					Cancer

Showing 1 to 10 of 4,383 entries

Diabetes

According to the World Health Organization, diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose (or blood sugar), which leads over time to serious damage to the heart, blood vessels, eyes, kidneys, and nerves. It affects approximately 422 mln people worldwide with about 1.5 mln deaths directly attributed to diabetes each year. In the framework of our project we will study the most acute problems associated with diabetes treatment in close collaboration with medical doctors from Department of Endocrinology of Osmania General Hospital and Osmania Medical College, Hyderabad, India.

Leishmaniasis

According to the World Health Organization, there are 3 main forms of leishmaniases – visceral (the most serious), cutaneous (the most common), and mucocutaneous. Leishmaniasis is caused by the protozoan Leishmania parasites which are transmitted by the bite of infected female phlebotomine sandflies. In the framework of our project we will investigate the existing targets for antileishmanial drugs, and try to identify the novel promising targets and their ligands that may improve the curation of the disease.

Cancer

According to the World Health Organization, cancers (malignant tumors, neoplasms) are one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths. Cancer is a generic term for a large group of diseases with a complex etiology. In the framework of our project we will focus on a breast cancer, particularly on a triple negative form, which is not associated with the estrogen and progesterone hormones, or with the presence of too many HER2 receptors. In addition to design of antineoplastic compounds active against triple negative breast cancer (TNBC), we will try to identify the inhibitors of heat shock protein 70, which is overexpressed in breast cancer (Jagadish N. et al., 2016. DOI: 10.1186/s13046-016-0425-9). Ideally, the desired pharmaceutical agents have to combine the multitarget inhibitory activity on TNBC and Hsp70.
Tuberculosis

Tuberculosis (TB), is a common and potentially deadly infectious disease caused by species and subspecies of the Myocobacterium tuberculosis complex, primarily Mycobacterium tuberculosis. According to the World Health Organization, in 2015 there were about 10.4 mln new (incident) TB cases worldwide, including 480000 new cases of multidrug-resistant TB (MDR-TB) and an additional 100000 people with rifampicin-resistant TB (RR-TB) who were also newly eligible for MDR-TB treatment. In the framework of our project we will focus on identification of molecular targets and their combinations, action on which may be the most promising for treatment of MDR-TB.

Malaria

According to the World Health Organization, malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. In 2015 malaria affects approximately 212 mln people with 429000 deaths. In the framework of our project we will investigate the existing targets for antimalarial drugs, and try to identify the novel promising targets and their ligands that may improve the prevention and curation of the disease.

Epilepsy

According to the World Health Organization, epilepsy is a chronic noncommunicable illness of the brain that affects about 50 million people of all ages worldwide. Nearly 80% of the people with epilepsy live in low- and middle-income countries, and about three fourths of those people do not get the treatment they need. In the context of our project, we will focus on refractory (pharmacoresistant) epilepsy, which affect about 30% of epileptic patients, who may suffer from irreversible disabilities and pre-mature deaths. The mechanisms of refractory epilepsy are still unclear; however, many efforts are ongoing into discovery and development of novel antiepileptic agents with better therapeutic profiles. Better understanding of the heterogeneous nature of epilepsy and the multiple complex factors, which contribute to the abnormal neural discharges, will create the basis for progress in development of etiological rather than symptomatic therapies.

Pharmacological Targets

Loading .. Please wait

Diabetes

Leishmaniasis

Cancer

Tuberculosis

Malaria

Epilepsy

Pharmacological Targets